logo-loader

FSD Pharma advancing its Phase 1 study in Australia

Published: 11:29 10 Feb 2020 EST

FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE) CEO Raza Bokhari sat down with Proactive’s Christine Corrado at BIO CEO in New York. Bokhari says the Cobourg, Ontario-based company will initiate Phase 1 safety trials in patients for its lead drug candidate PP 101 micro-PEA in before the end of 1Q, aiming to treat symptoms related to fibromyalgia, a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues.

Rush Rare Metals Advances Two Key Projects: Uranium in Wyoming and Niobium...

Rush Rare Metals CEO Peter Smith joined Steve Darling from Proactive to share news about the mineral exploration company's focus on its Boxi Property in Quebec and the Copper Mountain Project in Wyoming. The company recently announced the staking of the Knob claims in Wyoming, comprising 52...

27 minutes ago